22 May 2023
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Results of AGM
Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, held its Annual General Meeting ("AGM") earlier today at the offices of Simmons & Simmons LLP, CityPoint, 1 Ropemaker St, London EC2Y 9SS.
Ordinary resolutions 1 to 6 were duly passed along with special resolution 8. Special resolution 7 was not passed.
Proxy votes were received in respect of approximately 61% of the Company's issued share capital and the final votes received in respect of each resolution were as follows:
| Resolution | Number of votes for | % Votes for | Number of votes against | % | Number of votes withheld |
| 1. To receive and adopt the reports of the Directors and auditor and the audited accounts of the Company for the year ended 31 December 2022
| 77,261,778 | 99.98% | 13,683 | 0.02% | 963 |
| 2. To re-elect as a Director, Gianluca Braguti who seeks re-election | 77,227,821 | 99.94% | 46,239 | 0.06% | 2,364 |
| 3. To re-elect as a Director Jerry Randall who seeks re-election | 77,203,609 | 99.94% | 48,239 | 0.06% | 24,576 |
| 4. To appoint Mark Adams as Non-Executive Director | 77,252,547 | 99.97% | 21,513 | 0.03% | 2,364 |
| 5. To appoint Evelyn Partners Limited as the auditor of the Company until conclusion of the next AGM | 77,248,712 | 99.97% | 25,749 | 0.03% | 1,963 |
| 6. THAT the Directors are authorised to allot shares in the Company | 57,570,442 | 74.50% | 19,703,618 | 25.50% | 2,364 |
| 7. THAT, if Resolution 6 is passed, the Directors are authorised to allot equity securities for cash | 49,242,983 | 63.73% | 28,031,077 | 36.27% | 2,364 |
| 8. The Company is authorised to make one or more market purchases of ordinary shares | 68,942,257 | 89.22% | 8,331,803 | 10.78% | 2,364 |
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900
Stephen Keys / Camilla Hume (Corporate Finance)
Michael Johnson (Sales)
Singer Capital Markets (Joint Broker)
Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20 74963000
Jonathan Dighe (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.